Compare PODD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PODD | PCVX |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.6B |
| IPO Year | 2007 | 2020 |
| Metric | PODD | PCVX |
|---|---|---|
| Price | $158.62 | $53.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 4 |
| Target Price | ★ $341.48 | $88.25 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $2,708,100,000.00 | N/A |
| Revenue This Year | $24.55 | N/A |
| Revenue Next Year | $19.18 | N/A |
| P/E Ratio | $118.53 | ★ N/A |
| Revenue Growth | ★ 30.73 | N/A |
| 52 Week Low | $148.31 | $28.64 |
| 52 Week High | $354.88 | $65.00 |
| Indicator | PODD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 39.51 |
| Support Level | N/A | $52.04 |
| Resistance Level | $205.95 | $56.04 |
| Average True Range (ATR) | 8.61 | 2.70 |
| MACD | -1.04 | -0.74 |
| Stochastic Oscillator | 24.16 | 39.45 |
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.